Treatment of Alzheimer's disease;Tratamiento de la enfermedad de Alzheimer

Revista de Neurologia

Volumn 35, Issue 9, 2002, Pages 850-859

  López, Oscar L ^a,b   Becker, J T ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Anti inflammatories; Cholinesterase inhibitors; Ginkgo biloba; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANIRACETAM; CATECHOLAMINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CYCLOSERINE; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; IDEBENONE; LEVACECARNINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; OXIRACETAM; PAPAVERINE; PIRACETAM; PRAMIRACETAM; PROPENTOFYLLINE; PROTEIN ANTIBODY; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ASSOCIATION CORTEX; CELL SURVIVAL; CHOLINERGIC NERVE CELL; COGNITION; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; FRONTAL LOBE; HUMAN; INFLAMMATION; MEDICAL LITERATURE; METABOLISM; MEYNERT BASAL NUCLEUS; NEOCORTEX; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OXIDATIVE STRESS; PARIETAL LOBE; PATHOPHYSIOLOGY; SENILE PLAQUE; TEMPORAL LOBE;

EID: 0345830976     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3509.2002005     Document Type: Conference Paper

References (185)

1. Mesulam M-M. Principles of Behavioral and Cognitive Neurology. Oxford: Oxford University Press; 2000.
2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
3. Becker JT, Boller F, López OL, Saxton J, McGonigle K. The natural history of Alzheimer's disease: Description of study cohort and accuracy of diagnosis. Arch Neurol 1994; 51: 585-94.
4. Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728-33.
5. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 1010: 184-92.
6. Mann DM, Marcyniuk B, Yates PO, Neary D, Snowden JS. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988; 14: 177-95.
7. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathology 1989; 135: 309-19.
8. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-68.
9. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
10. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65.
11. Hyman BT, Damasio AR, van Hoesen GW, Barnes CL. Alzheimer's disease and cell specific pathology isolates the hippocampal formation. Science 1984; 225: 1168-70.
12. Whitehouse P, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: Evidence from selective loss of cholinergic neurons in the Nucleus Basalis. Ann Neurol 1981; 10: 122-6.
13. Zubenko G, Moossy J. Major depression in primary dementia: Clinical and neuropathological correlates. Arch Neurol 1988; 45: 1182-6.
14. López OL, Kaufer D, Reiter CT, Carra J, DeKosky ST, Palmer AM. Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer's disease. Eur J Neurol 1996; 3: 153-5.
15. Emre M, Geula C, Mesulam M-M. Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in Alzheimer's disease. J Comp Neurol 1993; 336: 117-34.
16. Geula C, Mesulam M-M. Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neuroscience 1989; 33: 469-81.
17. Baskin DS, Browning JI, Pirozzolo FJ, Korporaal S, Baskin JA, Appel SH. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol 1999; 56: 1121-3.
18. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
19. Schroder H, Zilles K, Maelicke A, Hajos F. Immunohisto- and cytochemical localization of cortical nicotinic cholinoceptors in rat and man. Brain Res 1989; 502: 287-95.
20. Schroder H, Zilles K, Luiten PGM, Strosberg AD, Aghchi A. Human cortical neurons contain both nicotinic and muscarinic acetylcholine receptors: An immunocytochemical double-labeling study. Synapse 1989; 4: 319-26.
21. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies. Life Sci 1995; 56: 869-76.
22. Rodríguez-Puertas R, Pascual J, Vilaro T, Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997; 26: 341-50.
23. Xu HX, Sweeney D, Greengard P, Gandy S. Metabolism of Alzheimer beta-amyloid precursor protein: Regulation by protein kinase A in intact cells and in a cell-free system. Proc Natl Acad Sci U S A 1994; 93: 4081-4.
24. Klunk WE, Debnath ML, Koros AM, Pettegrew JW. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 1998; 63: 1807-14.
25. Nuydens R, de Jong M, Nuyens R, Comelissen F, Geerts H. Neuronal kinase stimulation leads to aberrant tau phosphorylation and neurotoxicity. Neurobiol Aging 1995; 16: 465-75.
26. Lee VMY. Regulation of tau phosphorylation in Alzheimer's disease. Ann N Y Acad Sci 1996; 777: 107-13.
27. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 2000; 6: 916-9.
28. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
29. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5.
30. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408: 975-9.
31. Anthony JC, Breitner JCS, Zandi PP, Meyer MR, Jurasova I, Norton MC, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache Count Study. Neurology 2000; 54: 2066-71.
32. McHeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
33. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer's and other neurodegenerative disease. Brain Res Rev 1995; 21: 195-6.
34. Mrak RE, Sheng JG, Griffin WST. Glial cytokines in Alzheimer's disease: Review and pathogenic implications. Hum Pathol 1995; 26: 816-23.
35. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 1994; 151: 1105-13.
36. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 537-47.
37. Collins JS, Perry RT, Watson B, Harrell LE, Acton RT, Blacker D, et al. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease genetics initiative: The NIMH Alzheimer disease genetics initiative. Am J Med Genetics 2000; 96: 823-30.
38. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11.
39. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000; 54: 588-93.
40. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A doubleblind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
41. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999; 57: 295-303.
42. Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol 1998; 89: 142-9.
43. Aisen PS. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 1997; 43: 143-9.
44. Aisen PS, Marin D, Fusco M, Baruch B, Ryan T, Davis KL. A pilot study of colchicine in Alzheimer's disease. Alzheimer's Res 1996; 2: 153-6.
45. Kisilevsky R. Anti-amyloid drugs: Potential in the treatment of diseases associated with aging. Drugs Aging 1996; 8: 75-83.
46. Weiner JL, Buhler AV, Whatley VJ, Harris RA, Dunwiddie TV. Colchicine in a competitive antagonist at human recombinant gamma-aminobutyric acidA receptors. J Pharmacol Exp Ther 1998; 284: 95-102.
47. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: Implications for cognition and aging. Neurology 1997; 48: S8-S15.
48. Urani A, Privat A, Maurice T. The modulation by neurosteroids of the copolamine-induced learning impairment in mice involves an interaction with sigmal (sigmal) receptors. Brain Res 1998; 799: 64-77.
49. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17 betaestradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology 2000; 54: 2212-7.
50. Shaywitz S, Shaywitz BA, Pugh KF, Fulbright RK, Skudlarski P, Mencl WE, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281: 1197-202.
51. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 1999; 52: 965-70.
52. Tang MX, Jacobs D, Stem Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-32.
53. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46: 1580-4.
54. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
55. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology 2000; 54: 2061-6.
56. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 1999; 88: 1015-32.
57. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995; 15: 6213-21.
58. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-51.
59. Fournier J, Steinberg R, Gauthier T, Keane PE, Guzzi U, Coude FX, et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 1993; 55: 629-41.
60. Eriksdotter JM, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-57.
61. Jonhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord 2000; 14: S31-S38.
62. Nabeshima T, Yamada K. Neurotrophic factor strategies for the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: S39-S46.
63. Ala T, Romero S, Knight F, Feldt K, Frey WH. GM-1 treatment of Alzheimer's disease: A pilot study of safety and efficacy. Arch Neurol 1990; 47: 1126-30.
64. Smith CM, Coogan JS, Hart S. Effects of physostigmine on memory test performance in normal volunteers. Psychopharmacology (Berl) 1986; 90: 364-6.
65. Crowell EB, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther 1967; 8: 409-14.
66. Duvosin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. JAMA 1968; 206: 1963-5.
67. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
68. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992; 268: 2523-9.
69. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
70. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Br Med J 1999; 318: 633-8.
71. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfield S, Ding C. A five-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
72. Harbaugh RE. Intracerebroventricular bethanechol chloride administration in Alzheimer's disease. Ann N Y Acad Sci 1988; 531: 174-9.
73. Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM. Intraventricular bethanechol infusion for Alzheimer's disease: Results of double-blind and escalating-dose trials. Neurology 1988; 38: 219-22.
74. Taylor P. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 1998; 51: S30-S35.
75. Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-15.
76. Soares JC, Gershon S. THA-historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995; 6: 225-34.
77. DeLapp N, Wu S, Belagaje R, Johnstone E, Little S, Shannon H, et al. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant), transfected into Chinese hamster ovary-m1 cells. Biochem Biophys Res Commun 1998; 244: 156-60.
78. Farde L, Suhara T, Halldin C, Nyback H, Nakashima Y, Swahn CG, et al. PET study of the M1-agonists [11C] xanomeline and [11C] butylthio-TZTP in monkey and man. Dementia 1996; 7: 187-95.
79. Wettstein A, Spiegel R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 1984; 84: 572-3.
80. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, et al. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 1998; 795: 179-90.
81. Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 1991; 27: 315-9.
82. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11: S16-S22.
83. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998; 12: 304-12.
84. Bodick NC, Offen WW, Levey AL, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465-73.
85. Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology 2000; 54: 421-6.
86. Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia 1996; 7: 47-52.
87. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebocontrolled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 736-42.
88. Smith CM, Swase M, Exton-Smith AN. Choline therapy in Alzheimer's disease. Lancet 1978; 2: 318.
89. Renvoize EB, Jerram T. Choline in Alzheimer's disease. N Engl J Med 1979;301:330.
90. Fovall P, Dysken MW, Lazarus LW. Choline bitartrate treatment of Alzheimer type dementias. Comm Psychopharmacol 1980; 4: 141-5.
91. Thal LJ, Rosen W, Sharpless S, Crystal H. Choline chloride fails to improve cognition in Alzheimer's disease. Neurobiol Aging 1981; 44: 24-9.
92. Brinkman SD, Smith RC, Meyer JS. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol 1982; 37: 4-9.
93. Dysken MW, Fovall P, Harris CM, Davis JM, Noronha A. Lecithin administration in Alzheimer's disease. Neurology 1982; 32: 1203-4.
94. Weintraub S, Mesulam M-M, Auty R. Lecithin in the treatment of Alzheimer's disease. Neurology 1983; 40: 527-8.
95. Rao AM, Hatcher JF, Dempsey RJ. Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP-choline neuroprotection. J Neurochem 2000; 75: 2528-35.
96. Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 2000; 92: 448-452.
97. Calvani M, Carta A. Clues to mechanism of action of acetyl-L-carnitine in the central nervous system. Dementia 1991; 2: 1-6.
98. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441-8.
99. Álvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Meth Find Exp Clin Pharmacol 1999; 21: 633-44.
100. Warach S, Lettigrew LC, Dashe JF, Pullicinto P, Lefkowitz DM, Sabounjian L, Hamett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 investigators. Ann Neurol 2000; 48: 713-22.
101. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2000; 4: CD000269.
102. Davidson M, Zemishlany Z, Mohs RC. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 1988; 23: 485-90.
103. Stein L, Belluzzi JD, Wise CD. Memory enhancement by central administration of norepinephrine. Brain Res 1975; 84: 329-35.
104. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287: 373-92.
105. Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, et al. Clonidine treatment of Alzheimer's disease. Arch Neurol 1989; 46: 376-8.
106. Crook T, Ferris S, Sathananthan G. The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacol Bull 1977; 13: 46-8.
107. Friedlich AL, Butcher LL. Involvement of free oxygen radicals in beta-amyloidosis: An hypothesis. Neurobiol Aging 1994; 15: 443-55.
108. Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992; 49: 1137-41.
109. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41: 1726-32.
110. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996; 47: 705-11.
111. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpho-tocopherol, or both as treatment for Alzheimer disease. N Engl J Med 1997; 336: 1216-22.
112. Yoshida S, Busto R, Watson BD, Santiso M, Ginsberg MD. Postischemic cerebral lipid peroxidation in vitro: Modification by vitamin E. J Neurochem 1985; 44: 1593-601.
113. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265-72.
114. Tariot PN, Sunderland T, Weingartner H. Cognitive effects of selegeline in Alzheimer's disease. Psychopharmacology (Berl) 1987; 91: 489-95.
115. Burke WJ, Roccaforte VH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial. J Am Geriatr Soc 1993; 41: 1219-25.
116. Lawlor BA, Aisen PS, Green C, Fine E, Schmeidler J. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 319-22.
117. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, Logan AG. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects. Neurology 1998; 50: 660-8.
118. Dysken M, Mendels J, LeWitt P. Milacemide: A placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503-6.
119. Bergamasco B, Scarzella L, LaCommare P. Idebenone: A new drug for the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994; 9: 161-8.
120. Nagai Y, Toshida T, Narumi S, Tauayama S, Nagaoaka A. Brain distribution of Idebenone and its effect on local cerebral glucose utilization in rats. Arch Gerontol Geriatr 1989; 8: 257-72.
121. Otomo E, Nanja E, Saso S, Narikawa H, Terao T, Yoshino Y, Sakuma T, Tsuchiya M, Nozaka M, Haynski M, Asada T, Merugo M. Clinical evaluation of Idebenone in patients with cerebrovascular disease. Ther Res 1985; 2: 703-15.
122. Otomo E, Abe H, Araki G, Ito E, Omae T, Nishimura T, Hasegawa K. Usefulness of CV-2619 tablets in patients with cerebrovascular disorders, etc. Non-blind controlled trial in comparison with calcium hopatenate. Therapeutic Res 1985; 3: 117-36.
123. Bruno V, Battaglia G, Copani A, Sortino MA, Canonico PL, Nicoletti F. Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neurosci Lett 1994; 178: 193-196.
124. Weiland F, Schutz E, Armstrong VW, Kuthe F, Heller C, Oellerich M. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solution. Transplantation 1995; 60: 444-51.
125. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, et al. Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease. Behav Brain Res 1997; 83: 117-22.
126. Nitta A, Murakami Y, Furukawa Y, Kawatsura W, Hayashi K, Yamada K, et al. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 401-7.
127. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997; 36: 73-82.
128. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, et al. Idebenone in senile dementia of the Alzheimer type: A multicenter study. Arch Gerontol 1992; 15: 249-60.
129. Ringheim GE. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 2000; 903: 529-34.
130. Schubert P, Ogata T, Miyazaki H, Marchini C, Ferroni S, Rudolphi K. Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. J Neural Transm Suppl 1998; 54: 167-74.
131. Mcrae A, Ling EA, Schubert P, Rudolphi K. Properties of activated microglia and pharmacologic interference by propentofylline. Alzheimer Dis Assoc Disord 1998; 12: S15-S20.
132. Wirtz-Brugger F, Giovanni A. Guanosine 3′, 5′-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: Protective effects of propentofylline. Neuroscience 2000; 99: 737-50.
133. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, et al. A 12-month, randomized, placebo-controlled trial of popentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord 1997; 8: 320-8.
134. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP. Pentoxifylline in cerebrovascular dementia. Am Geriatr Soc 1992; 40: 237-44.
135. Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. Propentofylline treatment for Alzheimer disease and vascular dementia: An economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord 2000; 14: 102-11.
136. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-22.
137. Mobius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 1999; 13: S172-S8.
138. Lipton SA. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 1992; 42: 1403-5.
139. Parsons CG, Danysz W, Quack G. Memantine is a clinically well-to-lerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999; 38: 735-67.
140. Muller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's disease. Pharmacopsychiatry 1995; 28: 113-24.
141. Gortelmeyer R, Pantev M, Parsons CG, Quack G. The treatment of dementia syndrome with akatinol memantine, a modulator of the glutamatergic system: Preclinical and clinical results. In von Wild K, ed. Spektrum der Meurorehabilitation. Munich: W. Zuckschwerdt Verlag; 1993. p. 50-6.
142. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46.
143. Riekkinen P, Ikonen S, Riekkinen M. D-cycloserine, a partial NMDA receptor-associated glycine-B site agonist, enhances reversal learning, but a cholinesterase inhibitor and nicotine has no effect. Neuroreport 1998; 9: 3647-51.
144. Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999; 156: 467-9.
145. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8: 226-30.
146. 2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol 1995; 26: 325-38.
147. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990; 27: 1133-42.
148. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian multi-infarct dementia trial. J Neurol Sci 2000; 175: 124-34.
149. Friedman E, Sherman KA, Ferris S, Schneck MK. Clinical response to choline plus piracetam in senile dementia: Relation to red-cell choline levels. N Engl J Med 1981; 304: 1490-1.
150. Wurtman RJ, Magil SG, Reinstein DK. Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci 1981; 28: 1091-3.
151. Ferris SH, Reisberg B, Crook T. Pharmacologic treatment of senile dementia choline: L-Dopa, piracetam and choline plus piracetam. In Corkin S, ed. Alzheimer's Disease: A Report of Progress (Aging, Vol. 19). New York: Raven Press; 1982. p. 475-81.
152. Bartus RT, Dean RL, Sherman KA. Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 1981; 2: 105-11.
153. Chouinard G, Annable L, Ross-Chouinard A. A doubleblind placebo-controlled study of piracetam in elderly psychiatric patients. Psychopharmacol Bull 1981; 17: 129.
154. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993; 43: 301-5.
155. Growdon JH, Corkin S, Huff FJ, Rosen TJ. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 1986; 7: 269-76.
156. Baumel B, Eisner L, Karukin M. Oxiracetam in the treatment of multiinfarct dementia. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 673-82.
157. Falsaperla A, Pret P, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 1990; 12: 376-84.
158. Green RC, Goldstein FC, Auchus AP, Presley R, Clark S, van Tuyl L, et al. Treatment trial of oxiracetam in Alzheimer's disease. Arch Neurol 1992; 49: 1135-6.
159. LaFrance WC, Lauterbach EC, Coffey CE, Salloway SP, Kaufer DI, Reeve A, et al. The use of herbal alternative medicines in neuropsychiatry. J Neuropsychiatr Clin Neurosci 2000; 12: 177-92.
160. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-15.
161. Glisson J, Crawford R, Street S. The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Nurse Pract 1999; 24: 28-46.
162. Klein J, Charrerlee SS, Loffeholz K. Phospholipid breakdown and choline release under hypoxic conditions: Inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 1997; 755: 347-50.
163. Sasaki K, Hatta S, Haga M. Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol 1999; 367: 165-73.
164. Taylor JE. Neuromediator binding to receptors in the rat brain: The effect of chronic administration of Ginkgo biloba extract. Presse Med 1986; 15: 1491-3.
165. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327-32.
166. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittel-Forschung/Drug Research 1991; 41: 773-80.
167. Kanoeski S, Hermann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996; 29: 47-56.
168. Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment on the elderly. Hum Psychopharmacol 1987; 2: 159-69.
169. Hofferberth B. Einfluss von Ginkgo biloba Extract auf neurophysiologische und psychometrische Messergeonisse bei Patienten mit himorganischen. Psychosyndrom ein Doppelbindstudie gegen Placebo. Drug Res 1989; 39: 918-22.
170. Vorberg G, Schenk N, Schmidt U. Wirksamkelt eines neuen Ginkgo biloba Extraktes bei 100 Patienten mit zerebraler insuffizienz. Herz Gefasse 1989; 9: 936-41.
171. van Dongen MCJM, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG. The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000; 48: 1183-94.
172. Waters C. Cognitive enhancing agents: Current status in the treatment of Alzheimer disease. Can J Neurol Sci 1988; 15: 249-56.
173. Raskin A, Gershon S, Crook TH, Sathananthan G, Ferris S. The effects of hyperbaric and normobaric oxygen on cognitive impairment in the elderly. Arch Gen Psychiatry 1978; 35: 50-6.
174. Mazurek MF, Beal F, Bird ED, Martin JB. Vasopressin in Alzheimer's disease: A study of postmortem brain concentrations. Ann Neurol 1986; 20: 665-70.
175. Bissette G, Reynolds G, Kilts CD, Widerlov E, Nemeroff CB.
176. Nolan KA, Black RS, Sheu KFR, Langberg J, Blass JP. A trial of thiamine in Alzheimer's disease. Arch Neurol 1991; 48: 81-3.
177. Tinklenberg J, Pfefferbaum A, Berger P. 1-Desamino-D-arginine vasopressin (DDAVP) in cognitively impaired patients. Psychopharmacol Bull 1981; 17: 206-7.
178. Peabody C, Thiemann S, Pigache R. Desglycinamide-9-srginine-8 vasopressin (DGAVP, Organon 5667) in patients with dementia. Neurobiol Aging 1985; 6: 95-100.
179. Desouza EG, Whitehouse PJ, Kuhar MJ, Price DL. Reciprocal changes in corticotropin releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 1986; 319: 593-5.
180. Tinklenberg J, Pigache R, Berger P, Kopell B. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patients. Psychopharmacol Bull 1982; 18: 202-4.
181. Reisberg B, Ferris SH, Anand R. Effects of naloxone in senile dementia: A double-blind trial. N Engl J Med 1983; 308: 721-2.
182. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 1996; 46: 401-5.
183. Savory J, Exley C, Forbes WF, Huang Y, Joshi JG, Kruck T, McLachlan DR, Wakayama I. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? J Toxicol Environ Health 1996; 48: 615-35.
184. Levesque L, Mizzen CA, McLachlan DR, Fraser PE. Ligand specific effects on aluminum incorporation and toxicity in neurons and astrocytes. Brain Res 2000; 877: 191-202.
185. McLachlan DRC, Dalton AJ, Kruck TPA, Bell NY, Smith WL, Kalow W, et al. Intramuscular w in patients with Alzheimer's disease. Lancet 1991; 337: 1304-8.